Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?

الملخص EN

Background.

Currently the choice of breast cancer therapy is based on prognostic factors.

The proliferation marker Ki-67 is used increasingly to determine the method of therapy.

The current study analyses the predictive value of Ki-67 in foreseeing breast cancer patients’ responses to neoadjuvant chemotherapy.

Methods.

This study includes patients with invasive breast cancer treated between 2008 and 2013.

The clinical response was assessed by correlating Ki-67 to histological examination, mammography, and ultrasonography findings.

Results.

The average Ki-67 value in our patients collectively (n=77) is 34.9 ± 24.6%.

The average Ki-67 value is the highest with 37.4 ± 24.0% in patients with a pCR.

The Ki-67 values do not differ significantly among the 3 groups: pCR versus partial pathological response versus stable disease/progress (P=0.896).

However, Ki-67 values of patients with luminal, Her2 enriched, and basal-like cancers differed significantly from each other.

Furthermore, within the group of luminal tumors Ki-67 values of patients with versus without pCR also differed significantly.

Conclusion.

Our data shows that the Ki-67 value predicts the response to neoadjuvant chemotherapy as a function of the molecular subtype, reflecting the daily routine concerning Ki-67 and its impressing potential and limitation as a predictive marker for neoadjuvant chemotherapy response.